Bosutinib + Bosutinib + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Kidney, Autosomal Dominant
Conditions
Polycystic Kidney, Autosomal Dominant
Trial Timeline
Dec 1, 2010 → Aug 1, 2014
NCT ID
NCT01233869About Bosutinib + Bosutinib + Placebo
Bosutinib + Bosutinib + Placebo is a phase 2 stage product being developed by Pfizer for Polycystic Kidney, Autosomal Dominant. The current trial status is completed. This product is registered under clinical trial identifier NCT01233869. Target conditions include Polycystic Kidney, Autosomal Dominant.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01233869 | Phase 2 | Completed |
Competing Products
20 competing products in Polycystic Kidney, Autosomal Dominant